Salvia BioElectronics B.V., a neurostimulation platform company targeting chronic migraine, today announced … Continue reading “Salvia BioElectronics raises EUR 26M (USD 31M) to develop innovative neurostimulation therapy for chronic migraine”
22 September 2020, London, Geneva & Jersey: Medicxi, the leading European life sciences … Continue reading “Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners”
Novo Ventures, the ventures arm of Novo Holdings, today announced that it … Continue reading “NOVO VENTURES CO-LEADS US$83M SERIES C FINANCING IN LAVA THERAPEUTICS”
ALAMEDA, Calif. and BASEL, Switzerland – September 8, 2020 – Exelixis, Inc. (Nasdaq: … Continue reading “Exelixis and NBE-Therapeutics Enter into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer”
SOUTH SAN FRANCISCO, Calif. (August 13, 2020) Mission Bio, Inc., the pioneer in high-throughput … Continue reading “Mission Bio Raises $70M in Series C Funding Led by Novo Holdings to Accelerate Development of Cancer Therapies with Single-cell Multi-omics”
G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, and Bionical Emas, a … Continue reading “G1 Therapeutics, Inc. and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States”
Novo Holding A/S, a world-leading life science investor with a focus on … Continue reading “Novo Holdings bolsters Principal Investments team with key US appointments”
As Head of Principal Investments, Christoffer Søderberg will be overall responsible for … Continue reading “Novo Holdings appoints Christoffer Søderberg as Head of Principal Investments”
Funding enables accelerated development of fermentation-derived next-generation food colorants Flagship product targeting … Continue reading “Novo Holdings leads seed round in Chromologics”
Amsterdam, The Netherlands, August 29, 2020 – Kiadis Pharma N.V. (“Kiadis” or … Continue reading “Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)”
F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening … Continue reading “F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent”
Novo Ventures, the ventures arm of Novo Holdings, today announces that its … Continue reading “Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing”
Industry Veteran and Immune Oncologist with over 35 years’ Experience in the … Continue reading “NBE-Therapeutics Appoints Erich Schlick as Chairman of the Board of Directors”
BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces that CSL … Continue reading “CSL Behring to become latest partner in BaseLaunch Phase II”
Josep Tabernero joins SAB and Julian Blagg elevated to SAB Chair Martin … Continue reading “NeoPhore Strengthens Scientific Leadership Team”
20 Years’ Industry Experience Managing Biotech Companies in US and Europe Aim … Continue reading “NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer”
EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical … Continue reading “ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19”
Fund+ strengthens portfolio with medical device company developing a novel ‘invisible’ sensor … Continue reading “Fund+ Leads EUR38 Million Series B Financing in Indigo Diabetes NV”
Sydney, Australia and Los Angeles, California 21 July 2020 – Clarity Pharmaceuticals, … Continue reading “Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2020 Optimum Strategic Communications All rights reserved.
Warnford Court
29 Throgmorton Street
London
EC2N 2AT
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
